改良CALGB 10403方案治疗中美洲青少年及年轻成人急性淋巴细胞白血病
该研究在墨西哥5个中心和危地马拉1个中心前瞻性评估了95例中位年龄23岁(范围14-49岁)的青少年及年轻成人急性淋巴细胞白血病患者,采用根据中低收入国家药物和资源可及性改良的CALGB 10403方案。诱导后完全缓解率87.8%,随访中28.3%患者复发,2年总生存率72.1%,治疗相关死亡率为9.5%。
要点
- 改良CALGB 10403方案在中美洲青少年及年轻成人急性淋巴细胞白血病中可行,2年总生存率72.1%。
- 高白细胞血症(HR 4.28;95%CI 1.81-10.10)和诱导后微小残留病(HR 4.67;95%CI 1.75-12.44)与更差的总生存相关。
- 诱导和巩固期间肝毒性发生率分别为51.6%和53.7%,治疗相关死亡率为9.5%。
核心结论
- 在中美洲实施改良CALGB 10403方案是可行的,并与临床结局改善和可控的安全性相关。
研究设计与样本
- 前瞻性评估95例中位年龄23岁(范围14-49岁)的急性淋巴细胞白血病患者,在墨西哥5个中心和危地马拉1个中心接受改良CALGB 10403方案治疗。
- 改良包括使用大肠埃希菌(Escherichia coli)门冬酰胺酶、以6-巯基嘌呤替代硫鸟嘌呤,以及在CD20+患者中使用利妥昔单抗。
主要发现
- 87.8%的患者在诱导后达到完全缓解。
- 随访期间28.3%的患者复发。
- 2年总生存率为72.1%。
- 与更差总生存相关的因素包括高白细胞血症(HR 4.28;95%CI 1.81-10.10)和诱导后微小残留病(HR 4.67;95%CI 1.75-12.44)。
- 大多数患者出现肝毒性,诱导期间发生率为51.6%,巩固期间为53.7%;治疗相关死亡率为9.5%。
局限性
- 原文指出中低收入国家可能无法获得其他地方实施的标准治疗,需要进一步研究以改善脆弱人群的结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mexico and Central America have a high incidence of acute lymphoblastic leukemia (ALL) in adolescents and young adults. Historically, this patient group has been treated using adult-based regimens, which entails a high rate of treatment-related mortality and a poor overall survival (OS). The use of the CALGB 10403, a pediatric-inspired regimen, has been proven effective in this patient subgroup. Nonetheless, low- and middle-income countries (LMICs) may present limited access to standard care treatments implemented elsewhere, warranting the need for further research to improve outcomes among vulnerable populations. In this study, we present the outcomes in terms of safety and effectiveness of using a modified CALGB 10403 regimen to reflect drug and resource availability in LMICs. Modifications included the use of Escherichia coli asparaginase,6-mercaptopurine instead of thioguanine and the use of rituximab among patients with CD20+. A total of 95 patients with a median age of 23 (range, 14-49) years treated with this modified scheme were prospectively assessed at 5 centers in Mexico and 1 in Guatemala. Among these, 87.8% achieved a complete response after induction. During follow-up, 28.3% of patients relapsed. Two-year OS rate was 72.1%. Factors associated with worse OS included hyperleukocytosis (hazard ratio [HR], 4.28; 95% confidence interval [CI], 1.81-10.10) and postinduction minimal residual disease (HR, 4.67; 95% CI, 1.75-12.44). Most patients presented hepatotoxicity (51.6% and 53.7% during induction and consolidation, respectively), and the treatment-related mortality was 9.5%. Overall, results highlight that implementing a modified CALGB 10403 regimen in Central America is feasible, and it is associated with improvements in clinical outcomes and a manageable safety profile.
引用
- Rangel-Patiño J, Lee-Tsai YL, Urbalejo-Ceniceros VI, et al. A modified CALGB 10403 in adolescents and young adults with acute lymphoblastic leukemia in Central America. Blood Adv. 2023. PMID: 37307212. doi:10.1182/bloodadvances.2023009754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。